SG&A Efficiency Analysis: Comparing Viatris Inc. and Ionis Pharmaceuticals, Inc.

SG&A Trends: Ionis vs. Viatris Over a Decade

__timestampIonis Pharmaceuticals, Inc.Viatris Inc.
Wednesday, January 1, 2014201400001499100000
Thursday, January 1, 2015371730001923500000
Friday, January 1, 2016486160002351400000
Sunday, January 1, 20171084880002564000000
Monday, January 1, 20182446220002397300000
Tuesday, January 1, 20192870000002503400000
Wednesday, January 1, 20203540000003344600000
Friday, January 1, 20211860000004529200000
Saturday, January 1, 20221510000004179100000
Sunday, January 1, 20232326000004650100000
Monday, January 1, 2024267474000
Loading chart...

Unleashing the power of data

SG&A Efficiency: A Tale of Two Companies

In the competitive landscape of pharmaceuticals, understanding operational efficiency is crucial. Over the past decade, Ionis Pharmaceuticals, Inc. and Viatris Inc. have showcased contrasting trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Ionis saw a significant increase in SG&A expenses, peaking in 2020 with a 1,660% rise from 2014. Meanwhile, Viatris consistently maintained higher SG&A expenses, reflecting its larger scale, with a notable 210% increase over the same period.

Key Insights

  • Ionis Pharmaceuticals: Experienced a sharp rise in SG&A expenses, indicating aggressive expansion or increased operational costs.
  • Viatris Inc.: Despite higher absolute expenses, Viatris's growth in SG&A was more stable, suggesting efficient scaling.

These trends highlight the strategic differences between the two companies, offering valuable insights for investors and industry analysts alike.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025